MedTrace Logo

Vortioxetine in the Treatment of Depression Associated With Head and Neck Cancers Undergoing Radiotherapy

NCT04818099 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 208

Last updated 2021-03-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effects of vortioxetine, once daily (QD), on mood disorders and cognitive dysfunction in patients with head and neck cancers undergoing radiotherapy.

Conditions

  • Radiation Injuries

Interventions

DRUG

Vortioxetine 10 mg

Vortioxetine will be used with a dosage of 10mg once a day, for 2 months.

OTHER

Placebo

Placebo will be used with a dosage of one tablet once a day for 2 months.

Sponsors & Collaborators

  • Sun Yat-sen University

    collaborator OTHER

  • Affiliated Cancer Hospital & Institute of Guangzhou Medical University

    collaborator OTHER

  • Brain Hospital Affiliated to Guangzhou Medical University

    collaborator UNKNOWN

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Yamei Tang · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-10
Primary Completion
2023-10-10
Completion
2024-04-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04818099 on ClinicalTrials.gov